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Abstract: Strategies to enhance the already established doublet chemotherapy regimen for lung
cancer have been investigated for more than 20 years. Initially, the concept was to administer
chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport
within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active
transport by using pharmaceuticals designed to target the genome of tumors. In the present study,
five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative
stage IIIa–IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative
Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy
using combined intratumoral-regional and intravenous route of administration. Cisplatin
analogues were injected at 0.5%–1% concentration within the tumor lesion and proven malignant
lymph nodes according to pretreatment histological/cytological results and the concentration
of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous
plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of
patients. To the best of our knowledge this is the first report of direct treatment of involved
lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without
any adverse effects. The initial overall survival and local response are suggestive of a better
efficacy compared to established doublet cisplatin–based systemic chemotherapy in (higher)
standard concentrations alone according to the UICC 7 database expected survival. An extensive
search of the literature was performed to gather information of previously published literature
of intratumoral chemo-drug administration and formulation for this treatment modality. Our
study shows a favorable local response, more than a 50% reduction, for a massive tumor mass
after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose
intravenous chemotherapy according to our protocol. These encouraging results (even in very sick
ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and
quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis
[TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from
conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the
way for broader applications of this technique. Finally, future perspectives of this treatment and
pharmaceutical design for intratumoral administration are presented.
Keywords: cisplatin, lymph nodes, chemotherapy, intratumoral, lung cancer

Introduction
Lung cancer treatment still remains a challenge. In the last decade an effort has been
made to identify the mechanisms and pathways of lung cancer.1,2 Pharmacoethnicity
in association with pharmacogenomics has also been investigated as the genetic
mutations of lung cancer differ among populations and therefore several
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targeted therapies present a higher rate of efficiency,
as is the case with epidermal growth factor receptor
mutation (EGFR).3–5 Pharmacogenetics have also been
investigated for conventional chemotherapy in lung cancer
in an effort to identify different pathways and mechanisms of
acquired resistance to conventional chemotherapy.6,7 Targeted
therapies have been approved as first line treatment for
specific genetic mutations and many pathways are still under
investigation.8 However, doublet chemotherapy still remains
the cornerstone of treatment for many patients.9
Chemotherapy drugs present non-specific cytotoxic activity, which in many cases induce adverse effects from systemic
administration. Patients have to stop their treatment and the
national health systems are affected by the additional hospitalization days and drugs administered.10 In an effort to enhance
the efficiency of conventional chemotherapy, several studies
have investigated the addition of immunomodulatory agents
with conventional chemotherapy and/or anti-vascular endothelial growth factors with targeted chemotherapy.11–14 However,
systemic side effect prevalence still remains the same.
Another conceptual approach, ie, the locoregional administration of chemotherapeutics has been promoted by many
groups either in the form of intratumoral chemotherapy
(ITC),15–17 brachytherapy,18 photodynamic therapy,19 mechanic
debulking,20,21 and aerosol chemotherapy.22–24 Locoregional
therapy uses chemicals, genes, biologics, free or formulated
drugs, and novel drug carrier systems, as a single therapy or
with radiation therapy,25–29 thermal,22,74 or non-thermal local
ablative methods. These studies were mostly intended to
establish the safety and efficacy of locoregional therapies and
investigate whether higher drug concentration could increase
efficiency and decrease or prevent systematic adverse effects.
Intratumoral drug administration was also investigated as a
method to sensitize the tumor to radiotherapy and systematic
chemotherapy.30 Nearly 30% of newly diagnosed patients with
lung cancer will develop respiratory distress, bleeding, atelectasis, and post-obstructive pneumonia due to partial or complete
airway obstruction.31 The tumor core consists of chemotherapy
resistant tumor cells and intratumoral chemotherapy has been
observed to sensitize these cells by delivering selected drugs
into different parts of the core with radioactive coils and other
agents for brachytherapy.30,32–34 In particular, it was observed
that nanocarriers for chemotherapy drugs lead to improved
drug diffusion and sustain release. In addition, brachytherapy
studies presented data were the radiation emitted from the coils
was only cytotoxic to the site of inplantation.30,35 It has also
been observed that local tumor response is accomplished more
quickly with local intratumoral drug administration.16,36
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Moreover, there are obstacles that have to be bypassed
with these treatment techniques, such as: (a) increased interstitial fluid pressure, (b) local hypoxia, (c) heterogeneous
distribution of drug formulations due to abnormal vascular
architecture, (d) extracellular matrix with collagen, elastin,
fibroblasts, and (e) structural abnormalities within the center of the tumor. There are two principal methods of drug
permeation of the tumor as a sum effect of diffusion and
distribution within the tumor: active and passive transportation, which can be combined with a physical (pre)treatment,
like heating the device to enhance uptake or diffusion,37–39
or with a cooling device.40 Several formulations have been
investigated either with passive or active transportation in
order to investigate their efficiency. In addition, carriers
have been added to several pharmaceuticals to prolong their
local release and diffusion rates.41,42 Nanocarriers have provided an effective method for drug accumulation within the
tumor due to the enhanced permeability and retention effect
(EPR) effect.43 The EPR effect has been also observed to be
enhanced with the addition of polyethylene glycol (PEG)
stealth molecules,44 and controlled by heat shock protein
32 and carbon monoxide.45 The present study illustrates our
initial experience with intratumoral chemotherapy compared
to previous published studies and we propose future avenues
for applications of this methodology.

Patients and methods
Patients and study design
Five patients stage IIIa–IV, performance status 2 (PS2) unfit
for surgery, radiation, and chemotherapy were included in the
trial. The trial was initiated in May 2009 and was approved
by our investigational review board (IRB; Table 1). One
additional patient was excluded from the trial when she
was diagnosed with mammarian carcinoma stage IV with
a stenotic tracheal metastasis and hypercapnia $60 mmHg
unfit for treatment with laser or argon-plasma-coagulation
or radiation; however, she was treated along the same line
of this protocol only with slightly different ITC mixture,
adding 2 mg mitomycin to 10 mg cisplatin, and observed
upon follow up. The staging was decided according to the
sixth edition of tumor node metastasis (TNM) classification
of non-small cell lung cancer (NSCLC) as the trial took
place in 2009 and 2010. All patients had relatively adequate
renal function allowing for the administration of at least
70% of the dose defined intravenous standard platinum
doublet protocol (or alternatively area under the curve
[AUC] 4 in case of carboplatin; defined by a level of serum
creatinine of Value1.5 mg/mL), hepatic enzymes (bilirubin
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Table 1 Patient characteristics
Patient
stage

ECOG

Local 4-week
response

Survival
(days)

Histology

1. IIIb (cT4N2Mx)
2. IV (cT34NxM1b)
3. IIIb (cT4N2M0)
4. IV (cT34N2M1b)
5. IIIa (cT4N1M0)
6. Mammarian
CA IV

2
2

PRPR+

311
429

Squamous
Squamous

2
2

PR+
PR-

496*
365

Squamous
Adeno

2
2

NC
Local CR

552*
319

Adeno
Adeno

Notes: *Alive upon end of follow-up, other patients died due to cancer-related
death. Average PR+ overall survival: 463 days; average PR- overall survival: 338 days.
PR+: reduction of .50% of initial volume; PR-: reduction of 25%–50% of initial
volume.
Expected median survival according to UICC 7 in ECOG 0–1 patients: IIIa 1/5, IIIb
2/5, IV 2/5 = ((1*14 m) + (2*10 m) + (2*6 m))/5 = 9.2 months = 276 days.
Achieved median survival in this ECOG 2 group along our protocol = 13.2 m = 397
days: This means a surplus of 43.8% median survival in comparison to expected
survival.
Abbreviations: PR, partial response; ECOG, Eastern Cooperative Oncology Group;
NC, no change; CR, complete response; Adeno, adenocarcinoma; CA, carcinoma.

of Value1.5 mg/dL), and hematologic function (absolute
neutrophil count of 1.5 × 103 mm3 and platelet count of 1.0
× 105 mm3). Patients included had symptomatic obstruction
of the trachea or of a major bronchus secondary to inoperable
histologically confirmed NSCLC. The patient population in
this study included only patients with disease confined to
one hemithorax and with the major tumor involvement in the
thorax. Two cases with Stage IV NSCLC showed single bone
metastasis in upper arm respectively in thigh. For such cases,
the therapeutic strategy was to relieve symptoms from the
bronchial tumor and to address metastatic bone deposit with
radiation therapy and bisphosphonates according to standard
oncologic care. Nearly complete airway obstruction, superior
to 50% occlusion of at least one major airway was required
for inclusion into the study. Other criteria were: isolated lobar
obstruction was included only if it was believed to contribute

to respiratory insufficiency, chronic (or continuous) bleeding
worsening the respiratory situation or post-obstructive
pneumonia, or all these conditions together. Patients with
small cell carcinoma were excluded, based on anticipated
rapid response to systemic chemotherapy or irradiation or
both that these patients often experience.46
All patient treatment sessions were recorded in order to
evaluate the therapeutic protocol (Figures 1–6). Criteria for
exclusion were: pregnancy or child-bearing potential without
using contraceptive methods, concurrent highly septic situations
due to poststenotic pneumonia infections (ie, requiring intravenous antibiotic therapy was allowed), an unstable or serious
concurrent medical condition (eg, recent myocardial infarction
and superior vena cava syndrome), recent major surgery, or
large-field radiation therapy or chemotherapy in the month
before entry. Patients were not allowed to receive any concurrent radiotherapy to the lungs, immunotherapy or investigational
agents while on the study. These criteria were chosen based on
previous publications (Table 2).16,47 Written informed consent
was obtained from each patient before study enrollment. Patient
characteristics upon admission are presented in Table 1.

Dose schedule and technical aspects
The protocol was based on previous publications in the field
of intratumoral chemotherapy.16,36,46–48 Previous groups treated
their patients with cisplatin 0.5%–4% ITC. In Germany, 0.5%
cisplatin is the concentration for intravenous administration;
although uncommon, other cisplatin concentrations are available through the hospital’s dispensary when buying cisplatin
as a salt. It is believed that upon intratumoral bolus injection,
cisplatin will diffuse systemically via lymphatic draining vessels and lymph nodes; such drainage may reach sentinel lymph
nodes that would be exposed to the drug as a consequence of
ITC and at a higher drug concentration than possible with intravenous administration of the same cisplatin amount (Figure 5).

Figure 1 X-ray from patient 1.
Notes: (A) X-ray upon diagnosis. (B) after one session (1 month). (C) and after two sessions (6 weeks after diagnosis).
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Figure 2 Patient 2 upon diagnosis.
Notes: (A) Vertical computed tomography image upon diagnosis with ans without contrast. (B) X-ray upon diagnosis. (C) bronchoscopy image upon diagnosis.

As lymph node involvement in lung cancer is a major concern
for local recurrence, we added the direct treatment of involved
lymph nodes by drug delivery through a transbronchial needle
aspiration (TBNA)-needle of an endobronchial ultrasound
(EBUS)-probe to enhance the efficacy over ITC only. This drug
delivery by an EBUS-needle (EBUS-transbronchial needle dosing [TBND]) is aiming at six passes per lymph node to optimize
the permeation of the drug. We have chosen this number as six
passes are the optimal number for EBUS-TBNA to get representative results of the whole lymph node volume.
A huge point of contention for the use of ITC is the under or
over-dosing due to the leakage or backflow of drug. Such “loss”

Figure 3 CT images from patient 2.
Notes: (A and C) CT upon diagnosis. (B and D) CT after 10 weeks.
Abbreviation: CT, computed tomography.
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if not quantified makes it very difficult to relate the dose to the
effect over a tumor or target volume unit. We think that even in
the case that intratumoral-volume leaks out of the tumor very
easily as a so called “downstream effect”, this intratumoral-loss
cisplatin dose will be reabsorbed by the alveoli and mucosa
in other lung areas and will act as a systemic administration.
In other words, ITC that uses aqueous platinum analog offers
the advantage of very high concentrations (eg, up to 70-fold
higher compared to the same amount of carboplatin given intravenously in ITC with polyethylene glycol (PEG)-carboplatin)49
with less systemic cytotoxicity but in the end it resembles an
established intravenous split schedule: the timely separation of
intratumoral and intravenous administration leads to the wellknown efficient intravenous split cisplatin protocols with two
dosages typically 6 to 7 days apart and therefore this dosing
regimen makes sense.50
ITC has been demonstrated in animal models with lung
cancer to induce a positive antitumor immunoresponse;51
meaning a significant reduction in tumor mass different
than the main site directly treated by ITC. The same has

Figure 4 Patient 2 bronchoscopy findings upon diagnosis and after 10 weeks of
therapy including four ITC-sessions and three reduced systemic carboplatin doublet
applications.
Notes: (A) Bronchoscopy image upon diagnosis. (B) Bronchoscopy image after
local intratumoral treatment.
Abbreviation: ITC, intratumoral chemotherapy.
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Injection
site

Airway
model

Tumor

Direct
spread

Lesions
Tumor cells

IF
Return to
systemic
circulation
via thoracic
duct and
subclavian
veins

Vascular
vessel

Lymph
node
Micrometastasis

Figure 5 Intratumoral chemotherapy model.
Notes: After the local administration, tumor necrosis is observed and
micrometastasis occurs through the local abnormal vascular architecture and
diffusion through the interstitial fluid.
Abbreviation: IF, interstitial fluid.

been proven in human beings using other local treatment
modalities in different cancers.52 This effect is believed or
has been partly proven to be caused by demonstrating vast
amounts of tumor cell debris toward immunocompetent
cells, which are stimulating the immune system to use these
“specific” antigens to induce a “specific” antibody reaction;
eg, auto-vaccination triggered by local treatment modalities.
The cornerstone of these mechanisms is an intact competent
immune system which could be negatively influenced by
acute administration of intravenous chemotherapy. This is
the second reason to separate intravenous from intratumoral
administration timing for the first 5–10 days of treatment.
A major factor affecting ITC-efficacy is the distribution
of the drug intratumorally. We treated the mass from all possible directions: from endoluminal or from transthoracical
direction if feasible under ultrasound or C-arm fluoroscopy
guidance due to local anatomy. We used direct central needle
insertion in lobar stenosis (with atelectasis, chronic bleeding, and/or post-stenotic pneumonia) and in central airway
stenosis .50%. Especially in lobar stenosis, the maneuverability of the needle in the peripheral site is highly reduced;
therefore, the needle tip was placed in the most distant part
of the tumor and then retracted 0.5 cm delivering at each
iv

iv

iv

Start------7d------14d ------21d------28d------35d------42d------49d------ 56d
ITC

ITC

ITC

ITC

ITC

ITC

Figure 6 Scheme of proposed intratumoral protocol. Timing of intravenous
4-week-cycle with weekly intratumoral chemotherapy.
Abbreviations: d, day; ITC, intratumoral; iv, intravenous.
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point a maximum of 1 mL ITC-drug. This approach was only
allowed if the needle path was clear inside the inner two thirds
of a post-stenotic atelectasis which could represent a tumor
portion. In the exophytic parts of mainly central tumors, we
additionally directly injected intratumorally and, furthermore,
surrounded the exophytic parts on the mucosal layer with
small injections (1 mL) intramucosally/superficially around
the tumor neck aiming at closing a circle around the tumor
neck at this layer. In case of mixed intra-extrabronchial
stenosis with a transmucosal part of bulk and/or involved
lymph nodes we treated this part of the tumor by EBUSTBND. In lymph nodes, we aimed at six passes with different angulations for EBUS-TBND. For masses that abutted
the thoracic wall, we used ultrasound guided percutaneous
transthoracic drug injection (transthoracic ultrasound [tts]
ITC) through only one transthoracic puncture receiving the
needle tip to the most distal part of the ultrasound picture of
the mass and injecting 1 mL ITC-drug after each 0.5 cm pulling step back toward the puncture point. This procedure was
repeatedly performed in different angulations with 30 degrees
difference in a three-dimensional manner and under bronchoscopy for controlling and calculating the “loss” amount
of ITC leaking out of tumor mass and dispersing rapidly
down toward the central airways – the so called downstream
effect of ITC. The downstream effect may result from the
typically inhomogeneous spongy tumor structure or separated
by septa, layers, or from puncturing of bronchioli lumen
still patent within the tumor. In order to better visualize the
downstream effect, we colored the cisplatin-ITC with indigo
carmine dye (0.5 mL/10 mL drug volume). If a downstream
effect occurred, the injection was stopped, the needle position was changed by retracting 1 cm, followed by the next
injection of 1 mL until the subpleural area adjacent to the
insertion point was reached. Then a new needle pathway with
different angulations was started at the most distal point of
the ultrasound picture. In case visualization by ultrasound
was not possible we used different angulations under c-arm
fluoroscopy control. All this was to achieve a best individual
distribution of the ITC-drug to cover up the major part of the
tumor volume and involved lymph nodes.
Furthermore, the calculation of the ITC-drug volume was
done along the lines of the formula by Monga53 using the help
of the computed tomography (CT)-scans (in mL ITC-drug):
Volume = 0.5*maximum height*maximum width
*maximum depth

(1)

covering approximately 1 mL of tumor with 1 mL of
ITC-drug. In this study, we were adding the volume for
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Table 2 Intratumoral therapy experience
Author

Methodology

Subjects

Cancer cells/
tissue

Response

Nanoparticles

Carriers

Reference

Jia et al

Intratumoral plus
doxorubicin
magnetic field
OK-432

In vitro/in vivo

Lewis lung cancer

√

Magnetic Fe3O4

PLGA

27

In vivo

√

–

–

80

Multifunctional
theranostic
liposome
drug delivery system
plus doxorubicin
Review
Review
5-fluorouracil,
mitomycin,
methotrexate,
bleomycin,
mitoxantrone,
cisplatin
Intratumoral-P53

In vitro/in vivo

Squamous lung
carcinoma
Squamous cell
carcinoma-4 tumor
cells

√

Magnetic

Liposomes

62

Review
Review
Patients

Review
Review
Lung cancer

Review
Review
√

Review
Review
–

Review
Review
–

Patients

Lung cancer

√

–

–

51
61
16
36
46
47
48
56
25

Akeda et al
Li et al

Goldberg et al
Brincker et al
Celikoglu et al

Fujiwara et al

Abbreviations: OK, lyophilized incubation mixture of group A Streptococcus pyogenes of human origin; PLGA, poly(lactic-co-glycolic acid).

involved lymph nodes which were measured by EBUS
during the diagnostic TBNA in addition to the CT-scans
prior to therapy. In case a downstream effect was observed,
we summed up each observed 1 mL (meaning suddenly
rapid unmeasured droplets) of “lost” ITC-drug after planned
injection of 1 mL ITC and added this amount afterwards to
another “additional” path with a different angulation until
the pre-therapeutic calculated ITC-volume was reached.
The consequence of this approach was that in the patients

with a downstream effect more ITC-volume than previously
calculated was used. In reality, this was observed in two
patients with no more than 10% additional volume only in
the transthoracical approach. We restricted ourselves to a
maximum of total ITC volume 2-fold of the pre-therapeutic
calculated ITC-volume. A CT-scan for reevaluation and recalculation of the ITC-volumes was repeated after two complete
intravenous cycles encompassed by four to six administrations of ITC. The minimal goal in these very sick patients

Table 3 Effects and safety features
Patient

Adverse effect

Positive effect

Comment

1

Enforced bleeding after 1 ITC
(infiltration of the LLL-vein)

PR– (main symptom was bleeding).

2

Vomiting, nausea, and hematotoxicity.
(1800 Leuc./uL) after first ITC with
100 mg cisplatin.
None

Stopped moderate chronical bleeding
after second ITC, no recurrence of
bleeding.
Could swallow again after second ITC
stopping muscle waste, walks alone.

3
4
5

6

None
Acute cytotoxicity in the complete ROL as COP
(including S3) radiological without clinical relevance
and spontaneous regression without any lasting
damage; needle was steered from inside at the
inner 2/3 margin of the lobar atelectasis which
occluded orifice S1+2 in ROL.
Fever for 3 days after ITC.

Relief of dyspnoea and mucous retention,
stopped chronical bleeding after first ITC.
Relief of retention, reduced pCO2.
None (slightly less back pain).

Local CR, no longer bleeding or
retention.

PR+; possible infiltration of the esophagus
in reference to thorax-CT. Hematotoxicity
as a proof of systemic effect.
PR+
PR-; heavy smoker until death.
NC

Local CR; acute short mediastinitis?
Breast cancer stage IV with tracheal
metastasis (out of protocol).

Abbreviations: CT, computed tomography; ITC, intratumoral chemotherapy; CR, complete response; COP, cryptogenic organising pneumonia; Leuc, leucocytes; ROL,
right upper lobe (rul); PR, partial response; pCO2, partial carbondioxide measurement; LLL, left lower lobe; S, subsegment; NC, no change.
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was to administer two cycles intravenous platinum doublet
every 3–4 weeks encompassed with at least four sessions
ITC. We hoped to achieve four cycles intravenous doublet
encompassed by 8–12 ITC-administrations timely separated
as mentioned above if the patient was willing to do so and
if the local (meanwhile regressed) anatomy was feasible to
inject. One potential limitation of this protocol was the fact
that these sick patients had to be treated weekly for the ITCadministration with aqueous cisplatin. In palliative patients,
too much time inside the hospital should be avoided.
Previous experience of intratumoral administration was
30–40 mg aqueous cisplatin demonstrating good tumor reduction and no adverse effects.16,36,46–48 Therefore we used cisplatin
1% for smaller masses and 0.5% cisplatin concentration for
larger masses to realize a compromise between injected volume and drug amount per tumor volume unit for optimization
of drug distribution and tumor coverage with ITC. It has to
be mentioned that it was allowable to use more than 40 mg
cisplatin per ITC-session, but not more than the (theoretical)
70% standard cisplatin intravenous amount in these very sick
patients. We restricted ourselves therefore to the maximal dose
of 100 mg cisplatin per ITC-session. In reality, this was only
used in one ITC-session, all other ITC-sessions were done with
10–50 mg cisplatin in total (average 24 mg cisplatin).
The drug injection rate for ITC was between 1 and
5 mL/minute: if the downstream effect occurred we stopped
injection at the preceding injection point and reduced our
velocity to 1 mL/minute at the next injection point after
retraction of the needle. If there was no downstream effect
with 1 mL/minute in the preceding injection point we elevated
our injection velocity to 5 mL/minute in the following injection point after retraction. All this was meant to optimize
the coverage of ITC-volume in the mass and the time per
treatment session. The treatment times for an ITC-session
covering tumor mass and node(s) (average mass dimensions:
7 cm; average number of nodes: 2) was between 25 and
60 minutes (average 38 minutes).

Pharmaceuticals
The following pharmaceuticals were used for weekly intratumoral chemotherapy 5–10 days apart from the intravenous administration: cisplatin/hospira solution for infusion
100 mg/100 mL vial BT × 1 vial × 100 mL (Hospira UK Ltd,
Queensway, Royal Leamington Spa, Warwickshire, UK) in
concentrations between 0.5% and 1%.
For intravenous chemotherapy, 70% of a standard
platinum analog containing doublet scheme repeating every
3–4 weeks with the following drugs was used: cisplatin

Drug Design, Development and Therapy 2013:7
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or carboplatin and one of the following drugs GEMZAR®
(Lilly USA LLC, Indianapolis, IN, USA; 200 mg/1 g vial),
etoposide, and vincristine.
The intravenous administration was separated from
ITC by 5–10 days. The protocol aimed to treat these very
sick patients was with at least two cycles of intravenous
administration encompassed by 4–6 intratumoral administrations, if feasible due to local anatomy. The intravenous
combination scheme was chosen based on the performance
status of the patients. Putting intravenous and intratumoral
administrations together means that between two intravenous
administrations it was possible to give an additional two or
three ITC-administrations (Figure 6).

Specific treatment effects
and complications
In summary, there was no severe adverse event in a total
of 22 ITC-sessions even in an ITC with 100 mg cisplatin
showing only a one-time moderate hematotoxicity with 1800
leukocytes/mL. This is striking as a proof of the concept that
ITC either passed through the lymphatic vessels or was downstreamed or reabsorbed by the bronchial mucosa and alveoli
to become systemically active. It is worth mentioning that for
all directly visible tumor masses the first injection with ITC,
regardless of the approach (endoluminal or transthoracic),
changed the tumor color to pale or white almost immediately
and sometimes after the injection of only 1 mL. This appears
to be an acute interruption of the perfusion or a “shock reaction” of the tumor. Another interesting observation was the fact
that in patients with chronic bleeding from the tumor or from
peritumoral vessels, the bleeding stopped after only one or two
ITC-sessions. No acute local toxic effect in the mucosa or in
the healthy central airways could be identified; no late stenotic
process after ITC-sessions occurred either. Similar findings
have been reported in previous studies (Table 1).16,36,46–48

Discussion
Intratumoral injection of chemotherapeutics is an efficient
and safe local therapeutic method. ITC as adjuvant therapy
using the protocol described herein showed, as in other
ITC-studies, an expected relief concerning the acute local
problems caused by stenosis, bleeding, or atelectasis in four
of five NSCLC patients in the protocol and in one patient
(out of protocol) with mammarian cancer and tracheal
metastasis.32,42,44,54–60 Moreover, this trial demonstrated for
the first time that direct treatment of involved lymph nodes
with ITC by aqueous cisplatin simultaneously to the tumor
mass is possible and safe. As the results concerning debulk-
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ing are similar to those of other studies, loss of ITC-volume
as a downstream effect seems to be negligible.32,42,44,54–60
Such a downstream effect was only seen with small “loss”
volumes in two patients only when applying transthoracical
ITC. It is worth mentioning that to the best of our knowledge
we applied for the first time this protocol using a dye and
simultaneous bronchoscopy during transthoracical approach
of ITC to control this unintended effect of downstreaming and
thereby optimized the application of aqueous cisplatin for ITC
in a transthoracical approach. A big difference in this study
compared to other studies was that we took this approach in
very sick ECOG 2 patients who were not eligible for standard
oncologic care procedures. Under general conditions these
patients would have only received best supportive care with
a survival prognosis around 3 months. Even comparing these
very sick patients with the actual database UICC 7, which is
referred to as ECOG 0–1 patients treated in general with full
standard dose of intravenous platinum doublet schedules, it
appears as if this simple and less toxic protocol is superior to
standard intravenous regimens with respect to not only quality of life but as well to overall survival measured as cancer
related death. For now, the technique described herein using
free drug is applicable everywhere and induces relatively low
costs compared to the so called personalized tumor treatment
with modern drugs like tyrosine-kinase-inhibitors.
However, there is much room for optimization and further
investigation into the formulations of the drugs administered in
this study is warranted.36,48,51,61 First, passive or active targeting
should be explored. Active targeting has the advantage that
the formulation will bind locally to tumor cells and will not
leak through the abnormal vascular structures. Toward this
end, several efforts have been made to identify molecules that
can target actively with or without an additional chemotherapy
agent the tumor mutations.62 Several molecules/pathways have
been investigated in lung cancer patients, such as Galectin-3
and Cyclin D1, however there are still no candidates for active
targeting. This is an example where molecules and pathways,
although similar in different tumors, play different roles.63 In
an effort to identify new methods of sustaining drug release,
co-encapsulation of magnetic Fe3O4 with chemotherapeutic
agents have been investigated.27,64 However, although this
method of local drug entrapment is effective in small animals,
it can be lethal in larger (.dogs) as a larger magnetic field
is required. Also, extravasation has been observed when the
drug formulation is injected superficially. Another method
of drug release which is under investigation by Patrick Le
Pivert (Interventional Drug Delivery Systems and Strategies
[ID2S2], Medical Cryogenics, Jupiter, FL, USA) is intratu-
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moral drug injection while simultaneously freezing tissue
locally.40 Another method for temporary local entrapment
based on passive transportation is the addition of epinephrine
with the cisplatin drug formulation.65 The pH release system
has also been investigated with chemotherapy, the principal
theory being that at a low pH (,6.5; acidic environment) the
formulated complex releases the encapsulated drug.27 In the
study by Callahan et al,66 for the first time a pH responsive
genetically encoded drug release nanoparticle system was
engineered. This pH delivery system is designed to release
drug formulations in the mildly acidic environment that prevails in the extracellular matrix (ECM) of many solid tumors.
Temperature-sensitive gels as an intratumoral sustain release
system were also investigated (β-Lapachone). This formulation can be combined in a drug formulation complex and act
as the trigger for the drug release.28
Furthermore, a new methodology for evaluating drug
formulations for intratumoral delivery has to be pursued.
Specifically, as previously presented in gene therapy studies,
prediction models for drug diffusion within the tumor have to
be established before initiation of drug administration.67 The
ITASSER ([http://zhanglab.ccmb.med.umich.edu], Ann Arbor,
MI, USA) software is an established evaluation method with
many applications that has been used in previous studies.67,68
Moreover, several other studies were performed using the
ITASSER methodology; however, they were all implemented
in other organs, but they did demonstrate both efficiency and
safety.30 Radioactive wires have been applied with or without
the combination of a chemotherapy agent. These studies
used nanoparticles for better tumor penetration and diffusion (Table 4).42,44,64,69,70 In these studies, it was observed that
healthy tissue was not affected by this therapy. In a study by
Watson et al70 an ultrasound methodology was investigated to
efficiently deliver nanoparticles in epithelial and epithelialmesenchymal transition tumors. Nanoparticles have also
been used in association with thermal ablation as a method
for enhancing drug delivery/diffusion within the tumor and
to enhance local cytotoxicity.29 Intratumoral gene therapy was
also investigated with or without the addition of a chemotherapy agent and or radiotherapy.44,67,71–73 In a gene therapy study
by Hanna et al72 the methodology of intratumoral injection was
presented making this study an example for others to follow.
In these studies, it was observed that larger particles have a
higher probability of being absorbed by macrophages. New
photo-absorbent agents have also been tested as intratumoral
therapy. Indocyanine green was conjugated with phospholipidpolyethylene glycol-monoclonal antibody (PL)-PEG-mAb
in order to create a formulation with slow clearance times.

Drug Design, Development and Therapy 2013:7

Drug Design, Development and Therapy 2013:7

Nanoparticles and
thermal ablation
CpG plus rituximab/
cyclophosphamide
Dendritic cells plus
cyclophosphamide/irradiation
Anti-gal human antibody
HMG-CoA reductase
inhibitor lovastatin
Sorafenib
Cisplatin/epinephrine

PELA fibers plus
hydroxycamptothecin
Parvovirus H-1
NLP-PEG, CLP-PEG plus
DOX

Core-loaded fibers with
hydroxycamptothecin
Propionibacterium acnes
SLC-Fc, CpG-ODN
Hu14.18-IL-2
Three nanoparticle
magnetic chain with doxorubicin
BC-819
mPEG-PCL-Docetaxel

Patients
Patients

Review
In vitro/in vivo

In vitro/in vivo

In vitro/in vivo

Review

In vivo
In vitro/in vivo

In vitro/in vivo

In vitro/in vivo
In vitro/in vivo

In vitro/in vivo
In vitro/in vivo
In vitro/in vivo
In vitro/in vivo

In vitro/in vivo

Nude rats
Patients
In vitro/in vivo
Review
In vitro
In vitro/in vivo

In vitro/in vivo

Subjects

CT-26 colon
carcinoma cell line
Review
HT29 human colon
carcinoma cells
Refractory sarcomas
Head neck

B-cell lymphoma

Review

Glioblastoma multiforme
H22 hepatoma cells

H22 hepatoma cells

B16 melanoma cell line
B16F10 murine melanoma model
NXS2 neuroblastoma Cell line
MAT B III tumorbearing animals
Pancreas
H22 hepatoma cells

Head-neck
Pancreas
Breast-ovarian
Review
Intratumoral implant
U87-MG human glioblastoma
cancer cells
H22 hepatoma cells

Pancreas

Cancer cells/tissue
–
√
–
–
Lipid nanoparticles
–
ICG-PL-PEG-mAb
–
–
–
–
Nano chain magnetic
particles
–
mPEG-PCL
PELA
–
DOX-NLPs,
DOX-CLPs,
DOX-NLP-PEG,
DOX-CLP-PEG
Review
–
–

√
√
√
√
Review
√
√
√
√
√
√
√

√
√
√

Review
√
√

Review
–
–
–

Review
√
√
√

√
√

Nanoparticles

Response

–
–

Review
–

–

–

Review

–
Cationic
liposomes, nanolipid particles

–
Poly
(caprolactone)
Poly(D,L-lactide)

–
–
–
–

Fibers

Nanoshells
–
–
Review
–
PL-PEG

–

Carriers

86
65

83
84
85

81

29

44

76
73

72
69

77
78
79
64

74
75

42
71
67
41
28

30

Reference

Abbreviations: FU, fluorouracil; PEG, polyethylene glycol;U-87-MG, human glioblastoma-astrocytoma, epithelial-like cell line; DOX, doxorubicin;B16, melanoma cell line; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; PL, polylactic; H22,
hepatoma cells; CT-26, colon carcinoma cell line; ODN, oligodeoxynucleotide; HT29, human colon carcinoma cell lines; B16F10, murine metastatic melanoma in the tails of C57BL/6 mice; TNFerade, a replication-deficient adenoviral vector that
expresses tumor necrosis factor-α (TUMOR NECROSIS FACTOR-α); BC-819, a plasmid comprised of the H19 gene regulatory sequences; mPEG-PCL, poly(caprolactone); PELA, poly(D,L-lactide); SLC-Fc, secondary lymphoid tissue chemokineFc; CLP, cationic liposomes; NLP, neutral liposomes; ICG-PL-PEG-mAb, Indocyanine green-polylactic-polyethylene glycol-integrin α(v)β(3) monoclonal antibody; AdGVEGR.TNF.11D, a replication-deficient adenoviral vector that expresses tumor
necrosis factor-α (TNF-α); Hu14.18-IL-2, an immunocytokine consisting of human IL-2 linked to hu14.18 mAb, which recognizes the GD2 disialoganglioside; NXS2, neuroblastoma cell line; MAT B, animals (inoculated with Mat B-III-uPAR cells).
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This drug formulation has numerous applications for several
cancer types.74 Moreover, fibers bearing chemotherapy agents
were constructed for intratumoral therapy and were evaluated
for their pharmacokinetic profile and efficiency in vitro and
in vivo.75,76 The fibers presented efficient tumor control and a
correlation with radiolabelled coils was established.
Immunotherapy as intratumoral therapy has also been
investigated: (a) Propionibacterium acnes induces immunestimulation by increasing interleukin-12, tumor necrosis
factor-α, and interferon-γ, 77 (b) secondary lymphoid
chemokine and unmethylated cytosine-phosphorothioateguanine-oligodeoxynucleotide were used to mobilize lymphocytes and dendritic cells and increased the infiltration of CD4+
T-cells and CD11c+ cells in the tumor mass with observed
reduction in tumor mass,78 (c) hu14.18-interleukin-2 administration resulted in increased natural killer (NK) group 2,
member D receptors on intratumoral NKG2A/C/E+NKp46+
NK cells,79 (d) OK-432 efficiently suppressed metastatic
squamous cell carcinoma lesion by inducing interferon-γ and
tumor necrosis factor-α,80 (e) pre-treatment with cyclophosphamide and oligodeoxynucleotides plus rituximab enhanced
immune activation against tumor cells and reduced tumor evolution,81 (f) dendritic cells and dendritic cells plus cyclophosphamide or paclitaxel at low doses enhanced immune system
activation,82,83 (g) anti-gal antibody injection.84 Furthermore,
several biomarkers were used specifically in intratumoral
therapies as independent predictive factors, such as T cells
and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, an inhibitor of lovastatin, as a formulation that
blocks local metastasis after irradiation.85
Recently, sorafenib, a multi-targeted tyrosine kinase inhibitor, was used in an effort to modify interstitial fluid pressure
(IFP) and vascular density.86 It was observed that sorafenib and
imatinib both decreased IFP, increased vascular endothelial
growth factor, human placental growth factor, stromal cellderived factor α, and decreased soluble vascular endothelial
growth factor receptor-2, and, consequently, disease control
was observed.
Finally, lymphatic vascular circulation biology plays a key
role in micrometastasis formation. Tumor cells are mobilized
from the tumor site to the lymphatics before returning to the
systemic vascular circulation.87–90 Lymphatics have thin walls
and low pressure and, in addition, they collect fluid of various
substances from the interstitium and return it to the vascular
circulation.53,90 The lymphatics also act as a filter for tumor
cells and although they redeposit cancer cells they additionally
destroy cancer cells using their immunomodulatory activity.87
Sentinel lymph node mapping has been well described with
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tracer substances. Specifically, it was observed that when a tracer
was injected through the bronchial wall the tracer was transported to the regional lymph nodes by local lymphatic drainage
within 20–60 minutes depending on the site of injections and
available lymph node vasculature.5,56,91,92 The same principle is
in effect with regard to cytotoxic drug tissue injection.
At this point, the authors would like to state that the
major limitation of this study is the small number of
patients; however, statistically significant overall survival
was observed P = 0.048 (Table 1). Thus, our data provide
us with the necessary support to evaluate this modality in a
larger prospective study.
Based on our data and published literature we are confident that intratumoral chemotherapy should be considered
for the following uses:16
a. As a debulking tool in central NSCLC with a high efficacy
rate of .75% after four weekly sessions of ITC, demonstrated efficacy in 378 published patients including this
trial over two decades in different countries;32,42,44,54,55–60
b. As an adjunct to standard therapies even now in healing
trials in PS2-patients with central obstructive palliative
NSCLC;
c. Five studies, including this trial using ITC as an adjunct
to different standard therapies, are observational studies
using different modalities (to the best knowledge
Phase IIb), but they have shown in 68 patients with
NSCLC IIIa–IV unexpected median survival with an
improvement of 21%–78% compared to UICC 7 data
(4–6 months in total);42,57,59,60
d. Direct treatment with ITC (cisplatin 0.5%–1%) of central
tumor mass and involved lymph nodes by EBUS-TBND
is possible without severe adverse effects;
e. Direct treatment with ITC (para-toluenesulfonamide) of
peripheral nodules in combination with standard carboplatin
doublet chemotherapy shows very promising results;60 and
f. ITC as an adjuvant local procedure in combination with
standard, timely separated intravenous protocols should
be tested against adjuvant radiotherapy especially in
regards to (reduced) toxicity and survival.
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